named programs · 4 · from sources
What they call their work
Collaborative Ecosystem Building
Forges partnerships among research institutions, biotech companies, and advocacy groups to accelerate translation of research into clinical applications
Glioblastoma Awareness Day
Annual awareness and fundraising initiative to educate the public and mobilize support for glioblastoma research
Scientific Advisory Board
Engages leading neuro-oncologists, immunotherapy experts, and life sciences investors to evaluate and guide high-impact research investments
Venture Philanthropy Investment Program
Strategically funds early-stage glioblastoma research and biotech startups in therapeutics, diagnostics, and care models, guided by a Scientific Advisory Board
activities · 4 groups
What they do
-
Cancer Research Funding 2 activities
- Applying venture philanthropy to accelerate glioblastoma scienceOperates as a venture philanthropy organization by applying venture creation methodologies to philanthropic investment, strategically de-risking and accelerating transformative science in neuro-oncology to deliver innovations to patients.
- Funding glioblastoma research and therapiesAllocates donations and raised funds to support research initiatives and therapies with high potential for impact on glioblastoma treatment, including awarding over $1.5 million in research grants to innovative studies at leading U.S. medical institutions since founding.
-
-
Biomedical Research and Innovation 1 activity
- Advancing glioblastoma research and therapeutic developmentConducts and supports research on clinical trial design, preclinical evaluation of therapeutics, and the development of innovative agents—including immunotherapeutics, molecular-targeting agents, anti-angiogenic reagents, and cytotoxins—for central nervous system tumors.
-
-
Cancer Awareness and Education Initiatives 1 activity
- Hosting Glioblastoma Awareness Day in New York CityHosts an annual Glioblastoma Awareness Day event in New York City, convening patients, caregivers, researchers, and advocates to raise visibility and foster community engagement around glioblastoma.
-
-
Endowment and Gift Fund Management 1 activity
- Sustaining long-term research funding through recycled investment returnsRecycles returns from investments back into the fund to maintain a continuous cycle of support for glioblastoma research and care innovation, ensuring sustained capital for high-impact initiatives.
-
financials · form 990 · fy2024
revenue
Total revenue$629K
Contributions & grants$615K98%
Program service revenue$00%
Investment income$14K2%
Other revenue$0
expenses
Total expenses$97K
Program expenses0%
Admin / overhead0%
Fundraising100%
Salaries & benefits$0
Grants paid out$0
Largest expense lineCompensation
balance sheet
Total assets$539K
Cash$1
Investments$532K
Liabilities$0
Net assets$539K
Liquid reserves65.5 mo
1 years on record · 2024–2024
leadership · form 990 part vii · fy2024
Who runs it
board members · 3
- MORRIS OFFIT — DIRECTOR
- NED OFFIT — PRESIDENT
- VINCENT RELLA — SECRETARY/TREASURER
relationships · 36
Who they work with
- Alterris Oncology Partner — Collaborates on early-stage biotech spinouts and therapeutic platforms for glioblastoma.
- Blast Glioblastoma Partner — Serves on the advisory board of the organization.
- Cancer Expert Now Partner — Serves on the advisory board of the organization.
- Columbia University Partner — GenoTwin, where Connor Dowling was founding CEO, was a spinout from Columbia University, reflecting institutional ties relevant to the Fund’s biotech strategy.
- Dana-Farber Cancer Institute Partner — Collaborates with the Center for Neuro-Oncology at Dana-Farber Cancer Institute through its Director, Dr. David A. Reardon, a member of the Scientific Advisory Board.
- Deerfield Management Company Partner — Dr. Brian Bizoza, a member of the Scientific Advisory Board, is a Partner at Deerfield Management Company.
- Duke University Medical Center Partner — Has a professional connection through Dr. David A. Reardon’s prior role as Associate Deputy Director at the Preston Robert Tisch Brain Tumor Center.
- Food and Drug Administration Government — Collaborates with FDA leaders in neuro-oncology drug development.
- Foundation for Biomedical Research Partner — Chair of the Board of Directors.
- Harvard Medical School Partner — Engages with Harvard Medical School through Dr. David A. Reardon, Professor of Medicine and member of the Scientific Advisory Board.
- Johns Hopkins Partner — Partners on breakthrough research to overcome historical bottlenecks in glioblastoma treatment.
- Johns Hopkins University School of Medicine Partner — Chetan Bettegowda, affiliated with the Daniel W. Offit Fund's Scientific Advisory Board, holds leadership roles including Director of the Department of Neurosurgery and Director of the Physician Scientist Training Program
- Memorial Sloan Kettering Cancer Center Partner — Collaborates with the Fund on glioblastoma research initiatives and clinical engagement.
- Memorial Sloan Kettering Cancer Center Partner — Institution where Dr. Alex Miller previously served as Assistant Professor and completed her fellowship.
- Musella Foundation for Brain Tumor Research and Information Partner — Serves on the advisory board of the organization.
- NYU Langone Partner — Partners on scaling critical care networks and patient-centric programs for glioblastoma.
- NYU Langone Health Partner — Hosts the Perlmutter Cancer Center where Dr. Alex Miller leads the Neuro-oncology program and co-directs the Brain and Spine Tumor Center.
- National Cancer Institute Government — Collaborates with NCI leaders in neuro-oncology research and drug development.
- National Children’s Cancer Society Partner — Serves on the advisory board of the organization.
- National Institutes of Health Government — Reviewed grants for NIH study sections for over 15 years.
- Northwell Health Partner — Partner institution working with the Fund on patient support and research programs.
- Paypal Partner — Third-party payment processor used for handling payments
- Preston Robert Tisch Brain Tumor Center Partner — Co-leads the center at Duke University focused on brain tumor research and treatment.
- Raul Rabadan Partner — Co-founded GenoTwin with Connor Dowling; as Head of Mathematical Genomics at Columbia University, his expertise informs the Fund’s scientific network.
- Scientific Advisory Board Partner — Guides the organization in evaluating and prioritizing high-impact research initiatives in neuro-oncology and immunotherapy.
- Scientific Advisory Board Partner — Leveraged to vet and identify promising scientific advances in glioblastoma research and care.
- Scientific Advisory Board Partner — Provides expert guidance in neuro-oncology, immunotherapy, and life sciences investing to inform research funding decisions.
- Stripe Partner — Third-party payment processor used for handling payments
- The EndBrainCancer Initiative Partner — Serves on the advisory board of the organization.
- The Johns Hopkins Hospital Partner — Chetan Bettegowda, affiliated with the Daniel W. Offit Fund's Scientific Advisory Board, serves as Neurosurgeon-in-Chief and Director of multiple brain tumor centers
+ 6 more
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative Ecosystem for Innovationmethodology: collaborative_ecosystem_buildingBy uniting research institutions, biotech companies, regulators, and clinicians in shared therapeutic development goals, we accelerate progress against glioblastoma because cross-sector collaboration de-risks and speeds the path from concept to clinic.
- Expert-Guided Venture Philanthropy Modelmethodology: venture_philanthropyBy applying venture philanthropy principles with rigorous scientific vetting through a Scientific Advisory Board, we accelerate high-impact, de-risked research and clinical translation in neuro-oncology because expert-guided prioritization identifies overlooked, high-potential opportunities that traditional funders miss.
- High-Risk, High-Reward Research Fundingmethodology: high-risk_innovation_fundingBy targeting early-stage, high-risk research that traditional funders overlook, we enable transformative breakthroughs in glioblastoma because innovation requires tolerance for risk that conventional mechanisms often lack.
- Immunotherapy-Centered Therapeutic Developmentmethodology: immunotherapy-focused researchBy focusing on immunotherapeutics as a core strategy, we improve outcomes in neuro-oncology because leveraging the body’s immune system offers a targeted, adaptive approach to attacking brain and spinal tumors.
- Translational Research Accelerationmethodology: translational_accelerationBy providing targeted capital and strategic mentorship, we bridge the gap between academic discovery and clinical application because early-stage innovations in neuro-oncology often fail to advance without non-traditional support structures.